FDA approves Allergan’s drug for longer eyelashes
BOSTON (Reuters) - Allergan Inc, the maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse.
Latisse is designed to treat a condition known as hypotrichosis of the eyelashes, which means a person does not have enough eyelashes.
The active ingredient in Latisse is bimatroprost, the same ingredient that is in Allergan’s glaucoma treatment Lumigan. Patients taking Lumigan found a side effect of the drug to be eyelash growth, prompting Allergan to study it for the new use.
Continue reading - Reuters Health
